In this article, we will discuss Lorlatinib (Dosage Overview). So, let’s get started.
Lorlatinib is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on
• crizotinib and at least one other ALK inhibitor for metastatic disease; or
• alectinib as the first ALK inhibitor therapy for metastatic disease; or
• ceritinib as the first ALK inhibitor therapy for metastatic disease.
The recommended dosage of Lorlatinib is 100 mg orally once daily, with or without food, until disease progression or unacceptable toxicity.
Swallow tablets whole. Do not chew, crush or split tablets. Do not ingest if tablets are broken, cracked, or otherwise not intact.
Take Lorlatinib at the same time each day. If a dose is missed, then take the missed dose unless the next dose is due within 4 hours. Do not take 2 doses at the same time to make up for a missed dose. Do not take an additional dose if vomiting occurs after Lorlatinib but continue with the next scheduled dose.